Final 12-month results of the ZILVERPASS-RCT of ZILVER PTX vs. bypass

ZILVER PTX treatment versus bypass surgery for the treatment of TASC C&D fempop lesions.
Final 12-month results of the ZILVERPASS study, first presented at LINC 2019.